PMID- 21704182
OWN - NLM
STAT- MEDLINE
DCOM- 20120305
LR  - 20220311
IS  - 1878-5832 (Electronic)
IS  - 1359-6446 (Linking)
VI  - 16
IP  - 17-18
DP  - 2011 Sep
TI  - Truncated HER2: implications for HER2-targeted therapeutics.
PG  - 810-6
LID - 10.1016/j.drudis.2011.06.003 [doi]
AB  - The HER2 receptor is currently one of the flagship therapeutic targets in 
      clinical oncology. Trastuzumab, an antibody targeting HER2, has become a 
      foundation of care in women with HER2-positive breast cancer. However, many women 
      with metastatic breast cancer do not respond to trastuzumab-based therapy. One 
      possible source of trastuzumab resistance is the presence of truncated forms of 
      HER2 in the tumor. Numerous studies suggest that detection of truncated HER2 in 
      the tumor should result in modification of the classical therapeutic approach. 
      Recent development of several promising compounds brings hope that a generation 
      of novel therapeutic modalities against HER2-positive cancers will be delivered 
      in the future.
CI  - Copyright (c) 2011. Published by Elsevier Ltd.
FAU - Zagozdzon, Radoslaw
AU  - Zagozdzon R
AD  - Cancer Biology and Therapeutics Group, UCD Conway Institute, UCD School of 
      Biomolecular and Biomedical Science, University College Dublin, Belfield, Dublin 
      4, Ireland. radoslaw.zagozdzon@ucd.ie
FAU - Gallagher, William M
AU  - Gallagher WM
FAU - Crown, John
AU  - Crown J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110616
PL  - England
TA  - Drug Discov Today
JT  - Drug discovery today
JID - 9604391
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Breast Neoplasms/*drug therapy/*enzymology/genetics/pathology
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Receptor, ErbB-2/*genetics/*metabolism
MH  - Structure-Activity Relationship
EDAT- 2011/06/28 06:00
MHDA- 2012/03/06 06:00
CRDT- 2011/06/28 06:00
PHST- 2011/03/21 00:00 [received]
PHST- 2011/05/05 00:00 [revised]
PHST- 2011/06/06 00:00 [accepted]
PHST- 2011/06/28 06:00 [entrez]
PHST- 2011/06/28 06:00 [pubmed]
PHST- 2012/03/06 06:00 [medline]
AID - S1359-6446(11)00181-4 [pii]
AID - 10.1016/j.drudis.2011.06.003 [doi]
PST - ppublish
SO  - Drug Discov Today. 2011 Sep;16(17-18):810-6. doi: 10.1016/j.drudis.2011.06.003. 
      Epub 2011 Jun 16.